🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

First Affiliated Hospital of Ningbo University clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with First Affiliated Hospital of Ningbo University as lead sponsor. Synced 26 Sep 2026
21Current trials
10Recruiting now
6Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

First Affiliated Hospital of Ningbo University is the lead sponsor of 21 current clinical trials in our China register. 10 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Cadonilimab, Carboplatin, paclitaxel and Chidamide. The most-studied condition is Bronchiectasis.

ClinicalTrials.gov trials by status

  • Recruiting1048%
  • Not yet open419%
  • By invitation733%

Trials by phase

  • Not applicable838%
  • Observational838%
  • Phase 4314%
  • Phase 2210%
01

Clinical trials sponsored by First Affiliated Hospital of Ningbo University

21 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Effect of Mycobacterial Infection on Immune Status
NCT07638670 · ClinicalTrials.gov ↗ · Tuberculosis
Observational Recruiting 2025-07 China
Value of Bronchoalveolar Lavage with Acetylcysteine in the Treatment of Bronchiectasis.
NCT06726356 · ClinicalTrials.gov ↗ · Bronchiectasis with Acute Exacerbation
Not applicable Recruiting 2024-08 China
Immune Status and Disease Control of Inflammatory Airway Diseases
NCT07493629 · ClinicalTrials.gov ↗ · Airway Inflammation, Chronic Obstructive Pulmonary Disease (COPD), Asthma (Diagnosis)
Observational Recruiting 2025-08 China
Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy
NCT06758037 · ClinicalTrials.gov ↗ · DLBCL, Diffuse Large B-Cell Lymphoma
Drug: Chidamide
Phase 2 Recruiting 2025-01 China
Efficacy and Safety of Bronchoscopic Local Amikacin Instillation for Acute Exacerbations of Bronchiectasis in Adults: A Multicenter, Blinded, Randomized Controlled Trial
NCT07813299 · ClinicalTrials.gov ↗ · Bronchiectasis With Acute Exacerbation
Not applicable Recruiting 2026-05 China
Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy
NCT07030881 · ClinicalTrials.gov ↗ · Asthma, COPD
Not applicable Recruiting 2025-06 China
Remote Anxiety Management for ICS-resistant Asthma Study
NCT06732141 · ClinicalTrials.gov ↗ · Asthma
Not applicable Recruiting 2024-12 China
Effectiveness and Safety of Sodium Bicarbonate Pleural Lavage in the Treatment of Complex Pleural Effusion
NCT06734481 · ClinicalTrials.gov ↗ · Complicated Pleural Effusion/ Empyema
Not applicable Recruiting 2024-04 China
CHiR Therapy for Elderly DLBCL Intolerant to Chemo
NCT06764017 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma
Phase 2 Recruiting 2025-02 China
Effects of Environmental Fungal Exposure on Bronchial Asthma, ABPA and Bronchiectasis
NCT07313904 · ClinicalTrials.gov ↗ · Environmental Exposure, Asthma, Bronchiectasis
Observational Recruiting 2025-07 China
Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk
NCT07347977 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Recurrence, Survival Analysis
Drug: Lidocaine
Not applicable Not yet open 2026-01 China
Red Dichromatic Imaging for Improving Post-Biopsy Bronchoscopic Field Visibility
NCT07653945 · ClinicalTrials.gov ↗ · Bronchoscopic Biopsy, Airway Lesion, Biopsy-related Bleeding
Observational Not yet open 2026-07 China
Development and Validation of a Risk Prediction Model for Ischemic Stroke in Acute Myocardial Infarction Without Comorbid Atrial Fibrillation
NCT07171892 · ClinicalTrials.gov ↗ · Myocardial Infarction
Observational Not yet open 2025-10 China
Clinical Utility of Needle-Based Confocal Laser Endomicroscopy for Peripheral Pulmonary Lesions
NCT07827326 · ClinicalTrials.gov ↗ · Peripheral Pulmonary Lesions
Observational Not yet open 2026-10 China
IIT Study on the Use of Medical Bio Glue for Repairing Meniscus Tears
NCT06878794 · ClinicalTrials.gov ↗ · Unilateral Meniscus Tear of the Knee Joint
Not applicable By invitation 2024-12 China
Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer
NCT06931808 · ClinicalTrials.gov ↗ · Localized Advanced Rectal Adenocarcinoma
Phase 4 By invitation 2025-03 China
Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
NCT06715501 · ClinicalTrials.gov ↗ · Locally Advanced Esophageal Squamous Cell Carcinoma, II-IIIB Stages
Not applicable By invitation 2024-12 China
Polycolistin E Sodium Mesylate Combined With Intravenous Atomization for Carbapenem Resistant Gram-negative Bacteria in Pulmonary Infection
NCT06907069 · ClinicalTrials.gov ↗ · Lung Infection Bacterial
Phase 4 By invitation 2025-01 China
Effect of Remazolam Besylate Combined With Remifentanil Analgesic Sedation on the Prognosis of Patients With Sepsis
NCT06731088 · ClinicalTrials.gov ↗ · Sepsis
Drug: Midazolam
Phase 4 By invitation 2025-01 China
Metabolic Characteristics of Plasma OxPLs in STEMI Patients.
NCT07382700 · ClinicalTrials.gov ↗ · STEMI - ST-segment Elevation Myocardial Infarction
Observational By invitation 2025-01 China
POCT Detection for Blood Concentration of Tirofiban in Acute Myocardial Infarction Based on Azo-POP Probe.
NCT06836531 · ClinicalTrials.gov ↗ · Acute Myocardial Infarction (AMI)
Observational By invitation 2025-03 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in First Affiliated Hospital of Ningbo University trials

6 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in First Affiliated Hospital of Ningbo University trials

30 conditions
Bronchiectasis2Diffuse Large B-Cell Lymphoma2Asthma2Unilateral Meniscus Tear of the Knee Joint1Non-Small Cell Lung Cancer1Recurrence1Survival Analysis1Bronchoscopic Biopsy1Airway Lesion1Biopsy-related Bleeding1Tuberculosis1Bronchiectasis with Acute Exacerbation1Airway Inflammation1Chronic Obstructive Pulmonary Disease (COPD)1Asthma (Diagnosis)1DLBCL1Bronchiectasis With Acute Exacerbation1Myocardial Infarction1Asthma, COPD1Localized Advanced Rectal Adenocarcinoma1Complicated Pleural Effusion/ Empyema1Environmental Exposure1ABPA1Locally Advanced Esophageal Squamous Cell Carcinoma1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China2110

A trial with sites in more than one country appears in each of those registers.

05

Questions about First Affiliated Hospital of Ningbo University trials

How many clinical trials does First Affiliated Hospital of Ningbo University sponsor?

First Affiliated Hospital of Ningbo University is the lead sponsor of 21 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are First Affiliated Hospital of Ningbo University trials recruiting?

Yes. 10 of its 21 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is First Affiliated Hospital of Ningbo University testing?

Its current trials name 6 drugs and biologicals as interventions. The most frequent are Cadonilimab (1), Carboplatin, paclitaxel (1), Chidamide (1), Lidocaine (1) and Midazolam (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.